TY - JOUR
T1 - Case series
T2 - MRD negativity assessment using 11C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma
AU - Ngai, Cheong
AU - Kumar, Shaji
AU - Chi-lai Ho, Garrett
AU - Chen, Sirong
AU - Chim, Chor Sang
N1 - Funding Information:
Not applicable. The authors received no financial support for the research, authorship, and/or publication of this article.
Publisher Copyright:
© The Author(s), 2021.
PY - 2021
Y1 - 2021
N2 - Complete response (CR) is an important favorable factor for survival in multiple myeloma (MM). However, CR patients continue to relapse, especially in the presence of minimal residual disease (MRD). Bone marrow (BM) MRD is predictive of progression-free survival (PFS) in MM. However, myeloma outside the BM aspiration site may result in subsequent relapse despite MRD-negativity. Therefore, positron emission tomography-computed tomography (PET-CT) based on F-fluorodeoxyglucose (FDG) is a complementary tool to monitor residual disease in MM. However, FDG may miss myeloma lesions that are not FDG-avid. On the other hand, 11C-Acetate (ACT) has been found to be a more sensitive and specific tracer than FDG in MM. Recently, the addition of daratumumab to bortezomib, thalidomide, dexamethasone (VTd) or bortezomib, lenalidomide, dexamethasone (VRd) backbone has been proven to improve outcomes. Herein, we report three newly-diagnosed MM patients achieving deep responses with imaging CR using ACT PET in addition to conventional immunofixation CR and MRD-negative CR after a 3-weekly daratumumab-based quadruplet induction regimen.
AB - Complete response (CR) is an important favorable factor for survival in multiple myeloma (MM). However, CR patients continue to relapse, especially in the presence of minimal residual disease (MRD). Bone marrow (BM) MRD is predictive of progression-free survival (PFS) in MM. However, myeloma outside the BM aspiration site may result in subsequent relapse despite MRD-negativity. Therefore, positron emission tomography-computed tomography (PET-CT) based on F-fluorodeoxyglucose (FDG) is a complementary tool to monitor residual disease in MM. However, FDG may miss myeloma lesions that are not FDG-avid. On the other hand, 11C-Acetate (ACT) has been found to be a more sensitive and specific tracer than FDG in MM. Recently, the addition of daratumumab to bortezomib, thalidomide, dexamethasone (VTd) or bortezomib, lenalidomide, dexamethasone (VRd) backbone has been proven to improve outcomes. Herein, we report three newly-diagnosed MM patients achieving deep responses with imaging CR using ACT PET in addition to conventional immunofixation CR and MRD-negative CR after a 3-weekly daratumumab-based quadruplet induction regimen.
KW - 3-weekly daratumumab
KW - C-Acetate PET
KW - MRD negativity
KW - newly diagnosed multiple myeloma
KW - quadruplet induction
UR - http://www.scopus.com/inward/record.url?scp=85116334450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116334450&partnerID=8YFLogxK
U2 - 10.1177/20406207211030369
DO - 10.1177/20406207211030369
M3 - Article
AN - SCOPUS:85116334450
VL - 12
JO - Therapeutic Advances in Hematology
JF - Therapeutic Advances in Hematology
SN - 2040-6207
ER -